Intra Cellular Therapies reported $3.16M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
ALKERMES ALKS:US 55.16M 1.48M
Biocryst Pharmaceuticals BCRX:US $ 0.24M 0.18M
Biogen BIIB:US $ 753.9M 93.8M
Bristol Myers Squibb BMY:US $ 2471M 115M
Esperion Therapeutics ESPR:US $ 7.12M 2.05M
Gilead Sciences GILD:US $ 1424M 1203M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Intra Cellular Therapies ITCI:US $ 3.16M 0.62M
JAZZ PHA JAZZ:US $ 115.28M 20.87M
Johnson & Johnson JNJ:US $ 7598M 357M
Nektar Therapeutics NKTR:US $ 5.32M 0.85M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Novartis NVS:US $ 3755M 245M
Redhill Biopharma RDHL:US $ 8.03M 2.4M
Supernus Pharmaceuticals SUPN:US $ 17.93M 0.94M
United Therapeutics UTHR:US $ 25.9M 8.7M
Vanda Pharmaceuticals VNDA:US $ 5.66M 0.57M